GHGuardant Health GH · NASDAQ
$185.31 +1.49% (+$2.72)
- Market cap
- $24.9B
- Enterprise value
- $25.5B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 21.0x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -29.3%
- Gross margin
- 65.0%
- Net margin
- -38.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.58
- Free float
- 96.0%
About the company
Guardant Health, Inc. is an American biotechnology company specializing in the development of advanced diagnostic tests for cancer detection. The company is known for its liquid biopsy technology, which allows non-invasive analysis of blood samples to identify genetic mutations and biomarkers associated with various types of cancer. Guardant Health focuses on improving early cancer detection, monitoring treatment response, and detecting recurrence, contributing to personalized oncology care and better outcomes for patients.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Helmy Eltoukhy
Employees
2,498
Headquarters
Palo Alto
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 30% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 38% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number